The Medical Research Council has invested £50 million in a new centre focused on mitochondrial diseases, in a move aimed at improving treatments for a group of genetic disorders that currently has no cure. The announcement, made on 5 August 2026, marks a major step for UK-led research into conditions that affect around one in 5,000 people and can lead to severe disability, progressive decline and premature death.
The new MRC Centre of Research Excellence in Mitochondrial Genome Therapeutics will bring together experts from multiple disciplines to study how mutations in mitochondrial DNA cause disease and to turn that knowledge into therapies. According to the MRC, the initiative is designed to build scientific foundations for entirely new therapeutic strategies and to position the UK as a global leader in the field. MRC announcement
Why mitochondrial disease research matters
Mitochondrial diseases are a broad group of inherited genetic disorders, and the MRC said they create significant unmet medical needs for patients and families. The council added that mutations in mitochondrial DNA are also increasingly linked to neurodegeneration, metabolic disease, cardiovascular failure and age-related deterioration, widening the possible impact of the research beyond inherited conditions alone.
Project lead Professor Michal Minczuk of the University of Cambridge said the centre will provide new approaches to understanding and treating disease caused by mutations in the mitochondrial genome. He said the goal is to establish a long-term UK research platform with the scale, expertise and infrastructure needed to drive progress in mitochondrial genome therapeutics.
A UK-led network with international partners
The centre will be led by the University of Cambridge and will partner with the University of Birmingham, the University of Manchester, Heidelberg University, the University of Queensland and the Imagine Institute in Paris. It will also work with charities including the Lily Foundation and with industry partners worldwide.
Dr Ceri Williams, Executive Director of Challenge Led Themes at the MRC, said the UK has long been at the helm of mitochondrial science, including work on mitochondrial replacement therapy that prevents the inheritance of mitochondrial DNA mutations. She said the new centre builds on that foundation and could radically transform health research by improving prevention, detection and treatment.
Liz Curtis, chief executive and founder of the Lily Foundation, said the charity is proud to be a named partner in the initiative. She said the project’s emphasis on patient perspectives from the outset is important, adding that families should help shape priorities as researchers work towards future treatments.
The new investment reflects a broader push to strengthen UK health research in areas where clinical need remains high and treatment options remain limited. For patients affected by mitochondrial disease, the hope is that this large-scale collaboration will accelerate progress from laboratory discovery to practical therapies.
Photo source: AI-generated or edited image
